(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. حسب Long Li (6555)

Selection frequencies plotted in decreasing order. حسب Hannah P. Rowe (7830599)

General procedure for the synthesis of A and A-c1. حسب Xueqin lu (22250795)

Cephalometric measurement points. حسب Lijuan Liu (136685)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. حسب Søren Egstrand (10906087)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. حسب Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

¹³C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …"

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. حسب Xueqin lu (22250795)

Kylo-0603’s EC50 & tissue levels. حسب Xueqin lu (22250795)

DIO Mice Liver Staining. حسب Xueqin lu (22250795)

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. حسب Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). حسب Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. حسب Xueqin lu (22250795)